- OMIC Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
S-8 Filing
Singular Genomics Systems (OMIC) S-8Registration of securities for employees
Filed: 2 Mar 23, 4:31pm
As filed with the Securities and Exchange Commission on March 2, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
Registration Statement
Under
The Securities Act of 1933
Singular Genomics Systems, Inc.
(Exact name of Registrant as specified in its Charter)
Delaware |
| 81-2948451 |
(State or other jurisdiction of |
| (I.R.S. Employer |
_____________________________________________________
3010 Science Park Road |
(858) 333-7830
(Address of Principal Executive Offices)
Singular Genomics Systems, Inc. 2021 Equity Incentive Plan
Singular Genomics Systems, Inc. 2021 Employee Stock Purchase Plan
(Full title of Plan)
Andrew Spaventa
Chief Executive Officer
and Chairperson of the Board
Singular Genomics Systems, Inc.
3010 Science Park Road
San Diego, CA 92121
(Name and address of agent for service)
(858) 333-7830
(Telephone number, including area code, of agent for service)
Copies to:
Ryan J. Gunderson | Dalen Meeter |
Gunderson Dettmer Stough Villeneuve | Chief Financial Officer |
Franklin & Hachigian, LLP | Singular Genomics Systems, Inc. |
3570 Carmel Mountain Road, Suite 200 | 3010 Science Park Road |
San Diego, CA 92130 | San Diego, CA, 92111 |
(858) 436-8000 | (858) 333-7830 |
————————————
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|
| Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
Pursuant to General Instruction E to Form S-8 under the 1933 Act, this Registration Statement is filed by Singular Genomics Systems, Inc. (the “Registrant”) for the purpose of registering 4,311,280 additional shares of common stock, par value $0.0001 per share (the “Common Stock”) under the 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan pursuant to the provisions of such plans that provide for automatic annual increases in the number of shares reserved for issuance thereunder. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statements on Form S-8 filed with the Commission on May 27, 2021 and March 14, 2022 (File Nos. 333-256568 and 333-263535) to the extent not superseded hereby.
PART II
Information Required in the Registration Statement
Item 3. Incorporation of Documents by Reference
Singular Genomics Systems, Inc., or the Registrant, hereby incorporates by reference into this Registration Statement the following documents:
All other reports and documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents. The Registrant is not, however, incorporating any documents or information that the Registrant is deemed to furnish and not file in accordance with SEC rules. Any statement contained in a document incorporated or deemed incorporated by reference in this Registration Statement will be deemed modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed incorporated by reference in this Registration Statement modifies or supersedes that statement.
Item 4. Description of Securities
Not applicable.
Item 5. Interests of Named Experts and Counsel
Not applicable.
Item 6. Indemnification of Directors and Officers
Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section 145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.
As permitted by the Delaware General Corporation Law, the Registrant’s amended and restated certificate of incorporation and amended and restated bylaws contain provisions relating to the limitation of liability and indemnification of directors and officers. The amended and restated certificate of incorporation provides that the Registrant’s directors will not be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability:
The Registrant’s amended and restated certificate of incorporation also provides that if Delaware law is amended after the approval by the Registrant’s stockholders of the certificate of incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the directors will be eliminated or limited to the fullest extent permitted by Delaware law.
The Registrant’s amended and restated bylaws provide that the Registrant will indemnify its directors and officers to the fullest extent permitted by Delaware law, as it now exists or may in the future be amended, against all expenses and liabilities reasonably incurred in connection with their service for or on the Registrant’s behalf. The Registrant’s amended and restated bylaws provide that the Registrant shall advance the expenses incurred by a director or officer in advance of the final disposition of an action or proceeding, and permit the Registrant to secure insurance on behalf of any director, officer, employee, or other enterprise agent for any liability arising out of his or her action in that capacity, whether or not Delaware law would otherwise permit indemnification.
The Registrant entered into indemnification agreements with each of its directors and executive officers and certain other key employees. The form of agreement provides that the Registrant will indemnify each of its directors, executive officers and such other key employees against any and all expenses incurred by that director, executive officer, or other key employee because of his or her status as one of the Registrant’s directors, executive officers, or other key employees, to the fullest extent permitted by Delaware law, the Registrant’s restated certificate of incorporation and its amended and restated bylaws. In addition, the form agreement provides that, to the fullest extent permitted by Delaware law, the Registrant will advance all expenses incurred by its directors, executive officers and other key employees in connection with a legal proceeding.
The Registrant currently carries and intends to continue to carry liability insurance for its directors and officers.
Item 7. Exemption from Registration Claimed
Not applicable.
Item 8. Exhibits
The following exhibits are incorporated herein by reference.
EXHIBIT INDEX
Exhibit Number |
|
Description |
Form |
File No. |
Exhibit | Filing Date | Filed Herewith |
4.1 |
| S-1/A | 333-255912 | 4.1 | 5/24/2021 |
| |
4.2 |
| Amended and Restated Certificate of Incorporation of Registrant. | 8-K | 001-40443 | 3.1 | 6/1/2021 |
|
4.3 |
| 8-K | 001-40443 | 3.2 | 6/1/2021 |
| |
4.4 |
| 8-K | 001-40443 | 3.1 | 1/26/2022 |
| |
5.1 |
| Opinion and Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP. |
|
|
|
| X |
23.1 |
|
|
|
|
| X | |
23.2 |
| Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (contained in Exhibit 5.1). |
|
|
|
| X |
24.1 |
| Power of Attorney (contained in the signature page hereto). |
|
|
|
| X |
99.1 |
| 2021 Equity Incentive Plan as amended and restated, and forms of agreements thereunder. | 8-K | 001-40443 | 10.1 | 7/25/2022 |
|
99.2 |
| S-1/A | 333-255912 | 10.4 | 5/24/2021 |
| |
107 |
|
|
|
|
| X |
Item 9. Undertakings
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California on this 2nd day of March, 2023.
|
| Singular Genomics Systems, Inc. | |
|
|
|
|
|
| By: | /s/ Dalen Meeter |
|
|
| Dalen Meeter |
|
|
| Chief Financial Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Andrew Spaventa and Dalen Meeter and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorney-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Name and Signature |
| Title |
| Date |
|
|
|
|
|
/s/ Andrew Spaventa |
| Chief Executive Officer and Chair of the Board of Directors |
| March 2, 2023 |
Andrew Spaventa |
| (Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Dalen Meeter |
| Chief Financial Officer |
| March 2, 2023 |
Dalen Meeter |
| (Principal Financial Officer and Principal Accounting Officer) |
|
|
|
|
|
|
|
/s/ David Barker |
| Director |
| March 2, 2023 |
David Barker |
|
|
|
|
|
|
|
|
|
/s/ Kim Kamdar |
| Director |
| March 2, 2023 |
Kim Kamdar |
|
|
|
|
|
|
|
|
|
/s/ Elaine Mardis |
| Director |
| March 2, 2023 |
Elaine Mardis |
|
|
|
|
|
|
|
|
|
/s/ Michael Pellini |
| Lead Independent Director |
| March 2, 2023 |
Michael Pellini |
|
|
|
|
|
|
|
|
|
/s/ Jason Ryan |
| Director |
| March 2, 2023 |
Jason Ryan |
|
|
|
|
|
|
|
|
|